Michael Sheaff
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Michael Sheaff has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
- Aaron Scott Mansfield
Mayo Clinic
23 shared publications - Aimee Parsons
Leicester Cancer Research Centre, University of Leicester, Leicester, United Kingdom
23 shared publications Alan G. Dawson
23 shared publications- Andrew M. Fry
University of Leicester
23 shared publications Anita Singh
23 shared publications- Annabel Jane Sharkey
University of Sheffield Teaching Hospitals, Leicester, UK
23 shared publications
Latest Publications
- Open Access
- 8 July 2026
- Published by Wiley in Journal of Cutaneous Pathology
- Vol. 53 (12) , 1088-1096
Squamoid Eccrine Ductal Carcinoma: Case Series of a Rare, Potentially Aggressive Skin Cancer Associated With Immunosuppression
Squamoid Eccrine Ductal Carcinoma (SEDC) is a rare cutaneous adenexal carcinoma first described in 1997. It has distinct biphasic features on histology which commonly result in misdiagnosis as Bowen disease or cutaneous squamous cell carcinomas (cSCC) if diagnostic skin biopsies are too superficial. This may lead to a delay in diagnosis. It is locally aggressive with significant metastatic potential, and an association with immunosuppression has been previously reported in ~20% of cases. We conducted a single‐centre, retrospective cohort study of all patients diagnosed with SEDC over a 12‐year period (2013–2025). Ten cases were identified (7 M, 3 F; mean age at diagnosis 75 years [SD 10.8]), of whom 9 (90%) were immunocompromised due to solid organ transplantation ( n = 6) or haematologic malignancy ( n = 3). A diagnosis of SEDC was not initially made in any of the 4 cases in which an incisional biopsy was performed and only correctly diagnosed after complete excision. Locoregional recurrence occurred in 8 (80%) and distant metastasis in 2 (20%) of patients. Treatment included surgical excision in all cases, post‐operative radiotherapy due to incomplete or close margins or metastasis in 60%, and lymphadenectomy or parotidectomy in 20%. This case series highlights the diagnostic challenges posed by SEDC and the need for clinicopathologic vigilance, its potentially aggressive course, and the apparent strength of the association with immunosuppression which we propose may have been previously underestimated.
- 8 July 2026
- Published by Wiley in Journal of Cutaneous Pathology
- Vol. 53 (12) , 1088-1096
Open AccessSquamoid Eccrine Ductal Carcinoma: Case Series of a Rare, Potentially Aggressive Skin Cancer Associated With Immunosuppression
Squamoid Eccrine Ductal Carcinoma (SEDC) is a rare cutaneous adenexal carcinoma first described in 1997. It has distinct biphasic features on histology which commonly result in misdiagnosis as Bowen disease or cutaneous squamous cell carcinomas (cSCC) if diagnostic skin biopsies are too superficial. This may lead to a delay in diagnosis. It is locally aggressive with significant metastatic potential, and an association with immunosuppression has been previously reported in ~20% of cases. We conducted a single‐centre, retrospective cohort study of all patients diagnosed with SEDC over a 12‐year period (2013–2025). Ten cases were identified (7 M, 3 F; mean age at diagnosis 75 years [SD 10.8]), of whom 9 (90%) were immunocompromised due to solid organ transplantation ( n = 6) or haematologic malignancy ( n = 3). A diagnosis of SEDC was not initially made in any of the 4 cases in which an incisional biopsy was performed and only correctly diagnosed after complete excision. Locoregional recurrence occurred in 8 (80%) and distant metastasis in 2 (20%) of patients. Treatment included surgical excision in all cases, post‐operative radiotherapy due to incomplete or close margins or metastasis in 60%, and lymphadenectomy or parotidectomy in 20%. This case series highlights the diagnostic challenges posed by SEDC and the need for clinicopathologic vigilance, its potentially aggressive course, and the apparent strength of the association with immunosuppression which we propose may have been previously underestimated.
- 4 August 2025
- Published by Wiley in Cytopathology
- Vol. 36 (5) , 432-433
An International Collaborative for Reporting Lung Cytopathology
This editorial accompanies a series of articles related to the recently published WHO reporting volume on lung cytopathology. The articles complement and augment the information provided in the volume and they have been written by experts involved in the original publication.
- 4 August 2025
- Published by Wiley in Cytopathology
- Vol. 36 (5) , 432-433
An International Collaborative for Reporting Lung Cytopathology
This editorial accompanies a series of articles related to the recently published WHO reporting volume on lung cytopathology. The articles complement and augment the information provided in the volume and they have been written by experts involved in the original publication.
- 19 January 2025
- Published by BMJ in BMJ Case Reports
- Vol. 18 (1) , e262481
Relapsing ANCA-associated vasculitis presenting as a mediastinal mass
Anti-neutrophil cytoplasmic antibody-associated vasculitides (AAV) represent a heterogeneous multisystem group of disorders typified by necrotising inflammation of smaller blood vessels, classically yielding a pauci-immune, crescentic glomerulonephritis. Without prompt treatment, there is a significant risk of irreversible damage and ensuing renal impairment. Diagnosis is often challenging, exacerbated by the disorder’s often vague and insidious presentation. Even with known AAV, relapse can mimic other similarly serious conditions including infection or malignancy, with significant ramifications on respective downstream management options. Here, we present the case of a young man with pre-existing myeloperoxidase-positive vasculitis, describing a subacute cluster of symptoms and subsequently found to have an anterior mediastinal mass. Urgent tissue sampling excluded other aetiologies and ultimately delineated this as a surprising complication of vasculitis, allowing for prompt immunosuppression escalation. This case highlights the diagnostic challenge these patients represent, and the utility timely access to multimodality imaging holds alongside a multidisciplinary approach to expedite correct management decisions.
- 19 January 2025
- Published by BMJ in BMJ Case Reports
- Vol. 18 (1) , e262481
Relapsing ANCA-associated vasculitis presenting as a mediastinal mass
Anti-neutrophil cytoplasmic antibody-associated vasculitides (AAV) represent a heterogeneous multisystem group of disorders typified by necrotising inflammation of smaller blood vessels, classically yielding a pauci-immune, crescentic glomerulonephritis. Without prompt treatment, there is a significant risk of irreversible damage and ensuing renal impairment. Diagnosis is often challenging, exacerbated by the disorder’s often vague and insidious presentation. Even with known AAV, relapse can mimic other similarly serious conditions including infection or malignancy, with significant ramifications on respective downstream management options. Here, we present the case of a young man with pre-existing myeloperoxidase-positive vasculitis, describing a subacute cluster of symptoms and subsequently found to have an anterior mediastinal mass. Urgent tissue sampling excluded other aetiologies and ultimately delineated this as a surprising complication of vasculitis, allowing for prompt immunosuppression escalation. This case highlights the diagnostic challenge these patients represent, and the utility timely access to multimodality imaging holds alongside a multidisciplinary approach to expedite correct management decisions.
- Open Access
- 14 July 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (14) , 4109
Renal Transplant Outcomes in Plasma Cell Dyscrasias and AL Amyloidosis after Treatment with Daratumumab
Background: The morbidity and mortality from AL amyloidosis has significantly improved with the development of novel treatments. Daratumumab is a highly effective treatment for AL amyloidosis, but end-stage kidney disease is a common complication of this condition. Kidney transplantation is the ideal form of renal replacement therapy but has historically been contraindicated in this group of patients. Methods: Given the improved survival and better treatments of both conditions, we argue that it is time to reconsider transplanting these patients. Results: We report our experience of transplanting four patients with AL amyloidosis who had achieved stable remission through treatment with daratumumab. Conclusions: We highlight the key challenges involved and discuss important clinical issues for patients receiving daratumumab, particularly the difficulties with interpreting the crossmatch in light of daratumumab and immunoglobulin therapy interference. We also discuss the complexities involved in balancing the risks of infection, relapse, rejection, and immunosuppression in such patients.
- 14 July 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (14) , 4109
Open AccessRenal Transplant Outcomes in Plasma Cell Dyscrasias and AL Amyloidosis after Treatment with Daratumumab
Background: The morbidity and mortality from AL amyloidosis has significantly improved with the development of novel treatments. Daratumumab is a highly effective treatment for AL amyloidosis, but end-stage kidney disease is a common complication of this condition. Kidney transplantation is the ideal form of renal replacement therapy but has historically been contraindicated in this group of patients. Methods: Given the improved survival and better treatments of both conditions, we argue that it is time to reconsider transplanting these patients. Results: We report our experience of transplanting four patients with AL amyloidosis who had achieved stable remission through treatment with daratumumab. Conclusions: We highlight the key challenges involved and discuss important clinical issues for patients receiving daratumumab, particularly the difficulties with interpreting the crossmatch in light of daratumumab and immunoglobulin therapy interference. We also discuss the complexities involved in balancing the risks of infection, relapse, rejection, and immunosuppression in such patients.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Data from BRCA1/MAD2L1 Deficiency Disrupts the Spindle Assembly Checkpoint to Confer Vinorelbine Resistance in Mesothelioma
Mesothelioma is a universally lethal cancer lacking effective therapy. The spindle poison vinorelbine exhibits clinical activity in the relapsed setting, and in preclinical models requires BRCA1 to initiate apoptosis. However, the mechanisms underlying this regulation and the clinical implications have not been explored. Here, we show that BRCA1 silencing abrogated vinorelbine-induced cell-cycle arrest, recruitment of BUBR1 to kinetochores, and apoptosis. BRCA1 silencing led to codepletion of MAD2L1 at the mRNA and protein levels consistent with its status as a transcriptional target of BRCA1. Silencing of MAD2L1 phenocopied BRCA1 and was sufficient to confer resistance to vinorelbine. This was recapitulated in cell lines selected for resistance to vinorelbine, which acquired loss of both BRCA1 and MAD2L1 expression. Following ex vivo vinorelbine in 20 primary tumor explants, apoptotic response rate was 59% in BRCA1/MAD2L1-positive explants compared with 0% in BRCA1/MAD2L1-negative explants. In 48 patients, BRCA1 and/or MAD2L1 loss of expression was not prognostic; however, in a subset of patients treated with vinorelbine, survival was shorter for patients lacking BRCA1/MAD2L1 expression compared with double-positive patients (5.9 vs. 36.7 months, P = 0.03). Our data implicate BRCA1/MAD2L1 loss as a putative predictive marker of resistance to vinorelbine in mesothelioma and warrant prospective clinical evaluation.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from BRCA1/MAD2L1 Deficiency Disrupts the Spindle Assembly Checkpoint to Confer Vinorelbine Resistance in Mesothelioma
Mesothelioma is a universally lethal cancer lacking effective therapy. The spindle poison vinorelbine exhibits clinical activity in the relapsed setting, and in preclinical models requires BRCA1 to initiate apoptosis. However, the mechanisms underlying this regulation and the clinical implications have not been explored. Here, we show that BRCA1 silencing abrogated vinorelbine-induced cell-cycle arrest, recruitment of BUBR1 to kinetochores, and apoptosis. BRCA1 silencing led to codepletion of MAD2L1 at the mRNA and protein levels consistent with its status as a transcriptional target of BRCA1. Silencing of MAD2L1 phenocopied BRCA1 and was sufficient to confer resistance to vinorelbine. This was recapitulated in cell lines selected for resistance to vinorelbine, which acquired loss of both BRCA1 and MAD2L1 expression. Following ex vivo vinorelbine in 20 primary tumor explants, apoptotic response rate was 59% in BRCA1/MAD2L1-positive explants compared with 0% in BRCA1/MAD2L1-negative explants. In 48 patients, BRCA1 and/or MAD2L1 loss of expression was not prognostic; however, in a subset of patients treated with vinorelbine, survival was shorter for patients lacking BRCA1/MAD2L1 expression compared with double-positive patients (5.9 vs. 36.7 months, P = 0.03). Our data implicate BRCA1/MAD2L1 loss as a putative predictive marker of resistance to vinorelbine in mesothelioma and warrant prospective clinical evaluation.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Data from BRCA1/MAD2L1 Deficiency Disrupts the Spindle Assembly Checkpoint to Confer Vinorelbine Resistance in Mesothelioma
Mesothelioma is a universally lethal cancer lacking effective therapy. The spindle poison vinorelbine exhibits clinical activity in the relapsed setting, and in preclinical models requires BRCA1 to initiate apoptosis. However, the mechanisms underlying this regulation and the clinical implications have not been explored. Here, we show that BRCA1 silencing abrogated vinorelbine-induced cell-cycle arrest, recruitment of BUBR1 to kinetochores, and apoptosis. BRCA1 silencing led to codepletion of MAD2L1 at the mRNA and protein levels consistent with its status as a transcriptional target of BRCA1. Silencing of MAD2L1 phenocopied BRCA1 and was sufficient to confer resistance to vinorelbine. This was recapitulated in cell lines selected for resistance to vinorelbine, which acquired loss of both BRCA1 and MAD2L1 expression. Following ex vivo vinorelbine in 20 primary tumor explants, apoptotic response rate was 59% in BRCA1/MAD2L1-positive explants compared with 0% in BRCA1/MAD2L1-negative explants. In 48 patients, BRCA1 and/or MAD2L1 loss of expression was not prognostic; however, in a subset of patients treated with vinorelbine, survival was shorter for patients lacking BRCA1/MAD2L1 expression compared with double-positive patients (5.9 vs. 36.7 months, P = 0.03). Our data implicate BRCA1/MAD2L1 loss as a putative predictive marker of resistance to vinorelbine in mesothelioma and warrant prospective clinical evaluation.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from BRCA1/MAD2L1 Deficiency Disrupts the Spindle Assembly Checkpoint to Confer Vinorelbine Resistance in Mesothelioma
Mesothelioma is a universally lethal cancer lacking effective therapy. The spindle poison vinorelbine exhibits clinical activity in the relapsed setting, and in preclinical models requires BRCA1 to initiate apoptosis. However, the mechanisms underlying this regulation and the clinical implications have not been explored. Here, we show that BRCA1 silencing abrogated vinorelbine-induced cell-cycle arrest, recruitment of BUBR1 to kinetochores, and apoptosis. BRCA1 silencing led to codepletion of MAD2L1 at the mRNA and protein levels consistent with its status as a transcriptional target of BRCA1. Silencing of MAD2L1 phenocopied BRCA1 and was sufficient to confer resistance to vinorelbine. This was recapitulated in cell lines selected for resistance to vinorelbine, which acquired loss of both BRCA1 and MAD2L1 expression. Following ex vivo vinorelbine in 20 primary tumor explants, apoptotic response rate was 59% in BRCA1/MAD2L1-positive explants compared with 0% in BRCA1/MAD2L1-negative explants. In 48 patients, BRCA1 and/or MAD2L1 loss of expression was not prognostic; however, in a subset of patients treated with vinorelbine, survival was shorter for patients lacking BRCA1/MAD2L1 expression compared with double-positive patients (5.9 vs. 36.7 months, P = 0.03). Our data implicate BRCA1/MAD2L1 loss as a putative predictive marker of resistance to vinorelbine in mesothelioma and warrant prospective clinical evaluation.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S5 from BRCA1/MAD2L1 Deficiency Disrupts the Spindle Assembly Checkpoint to Confer Vinorelbine Resistance in Mesothelioma
Prognostic effect of MAD2L1 in second line cohort. Kaplan Meier curve for overall survival (OS) in patients treated with vinorelbine second line (n=3) stratified according to MAD2L1 expression
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from BRCA1/MAD2L1 Deficiency Disrupts the Spindle Assembly Checkpoint to Confer Vinorelbine Resistance in Mesothelioma
Prognostic effect of MAD2L1 in second line cohort. Kaplan Meier curve for overall survival (OS) in patients treated with vinorelbine second line (n=3) stratified according to MAD2L1 expression
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S1 from BRCA1/MAD2L1 Deficiency Disrupts the Spindle Assembly Checkpoint to Confer Vinorelbine Resistance in Mesothelioma
BRCA2 is not required for vinorelbine-induced cell death MSTO and REN cells were transfected with siNT and siBRCA2. 24 hours following transfection, cells were treated with vinorelbine 100 nM for a further 48 hours and caspase 3 activity measured. Data were normalised to untreated siNT control. Western blots show downregulation of BRCA2 after silencing. MSTO-211H: siNT NT vs siNT VNB p<0.0001; siBRCA2 VNB vs siBRCA2 VNB p<0.0001. REN: siNT NT vs siNT VNB p<0.0001; siBRCA2 VNB vs siBRCA2 VNB p<0.0001.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from BRCA1/MAD2L1 Deficiency Disrupts the Spindle Assembly Checkpoint to Confer Vinorelbine Resistance in Mesothelioma
BRCA2 is not required for vinorelbine-induced cell death MSTO and REN cells were transfected with siNT and siBRCA2. 24 hours following transfection, cells were treated with vinorelbine 100 nM for a further 48 hours and caspase 3 activity measured. Data were normalised to untreated siNT control. Western blots show downregulation of BRCA2 after silencing. MSTO-211H: siNT NT vs siNT VNB p<0.0001; siBRCA2 VNB vs siBRCA2 VNB p<0.0001. REN: siNT NT vs siNT VNB p<0.0001; siBRCA2 VNB vs siBRCA2 VNB p<0.0001.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S7 from BRCA1/MAD2L1 Deficiency Disrupts the Spindle Assembly Checkpoint to Confer Vinorelbine Resistance in Mesothelioma
Western blot images for replicates. Replicate images for figure 1, figure 2 and figure 3.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from BRCA1/MAD2L1 Deficiency Disrupts the Spindle Assembly Checkpoint to Confer Vinorelbine Resistance in Mesothelioma
Western blot images for replicates. Replicate images for figure 1, figure 2 and figure 3.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S5 from BRCA1/MAD2L1 Deficiency Disrupts the Spindle Assembly Checkpoint to Confer Vinorelbine Resistance in Mesothelioma
Prognostic effect of MAD2L1 in second line cohort. Kaplan Meier curve for overall survival (OS) in patients treated with vinorelbine second line (n=3) stratified according to MAD2L1 expression
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from BRCA1/MAD2L1 Deficiency Disrupts the Spindle Assembly Checkpoint to Confer Vinorelbine Resistance in Mesothelioma
Prognostic effect of MAD2L1 in second line cohort. Kaplan Meier curve for overall survival (OS) in patients treated with vinorelbine second line (n=3) stratified according to MAD2L1 expression